, a biopharmaceutical firm focused on developing and commercializing proved cancer therapies in brand-new orphan drug indications, presented extra preclinical data at the American Association of Tumor Research Developments in Brain Cancer Research Conference on the prospect of its lead product applicant VAL-083 to treat patients with temozolomide-resistant glioblastoma multiforme . Dennis Dark brown, DelMar's Chief and co-Founder Scientific Officer, presented an abstract entitled, ‘Dianhydrogalactitol inhibits the development of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo.’ The data from the in vitro portion and the first in vivo segments of the study previously reported at the 2015 AACR annual meeting demonstrated that: VAL-083 could be efficacious against both stem and non-stem GBM cell cultures, including those resistant to temozolomide ; VAL-083 preserved anti-tumor activity independent of DNA fix enzyme 0-6-methylguanine DNA methyltransferase resistance mechanism; VAL-083 demonstrated an additive effect when combined with radiation in every cultures tested, suggesting that VAL-083 may become a radiosensitizer in GBM; and VAL-083 was effective against GBM in significantly extending survival time in intracranial xenograft GBM versions in a dosage dependent manner, including in GBM xenografts that are resistant to TMZ traditionally.Agena Bioscience provides retained the employees of the acquired segment and will remain headquartered in San Diego, California. Agena Bioscience aims to progress the MassARRAY program, a proprietary platform used in unlocking biological understanding from genetic research. The vision is certainly to leverage the initial capabilities of the MassARRAY platform and make it an interesting and cost-effective genetic evaluation tool for use in clinical practice. We has been greatly impressed by the MassARRAY system's capacity to deliver accurate and cost-effective characterization of nucleic acids.